Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
L 'Oreal currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to HOERNER, PAUL ELLSWORTH, who is the busiest examiner for the portfolio. The portfolio's active prosecution involves 1 distinct examiner and a single distinct art unit.
This indicates a very specific focus for the company's current biotech-related filings. The outcome of the 1 pending office action will be the primary indicator of the company's success in this technology area. Practitioners should focus on the specific requirements of HOERNER, PAUL ELLSWORTH to resolve the active matter effectively.
The concentration in a single art unit suggests a targeted technical focus that has not yet expanded into broader pharmaceutical disciplines. Reliance on a single examiner means that the patent strategy is highly sensitive to the specific interpretations of that official. As the portfolio matures, diversifying across different examiners may help mitigate the risks associated with such a centralized prosecution profile.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBAS, ABDULRAHMAN MUSTAFA | 1 | 51.6% | +29.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257306 | PROCESS FOR TREATING HUMAN PERSPIRATION AND BODY ODORS USING MAGNESIUM OXIDE AND A PHOSPHATE SALT | ABBAS, ABDULRAHMAN MUSTAFA | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18257306 | PROCESS FOR TREATING HUMAN PERSPIRATION AND BODY ODORS USING MAGNESIUM OXIDE AND A PHOSPHATE SALT | ABBAS, ABDULRAHMAN MUSTAFA | 1612 | §103 | Final Rejection | — | Pending | Jun 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialL' Oreal has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Abdulrahman Mustafa Abbas has the most, with 1 of L' Oreal's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
